NCT00414388View on ClinicalTrials.gov

Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

September 30, 2011

Study Completion Date

March 31, 2012

Conditions
Prostate Cancer
Interventions
DRUG

Sorafenib

400mg twice daily

Trial Locations (2)

60068

Oncology Specialists, S.C, Park Ridge

60714

Onocology Specialists, S.C, Niles

All Listed Sponsors
lead

Oncology Specialists, S.C.

OTHER

NCT00414388 - Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer | Biotech Hunter | Biotech Hunter